Nitroxoline (Synonyms: 8-Hydroxy-5-nitroquinoline, 5-Nitro-8-hydroxyquinoline) |
Catalog No.GC11365
One-Click Copy Product Info
|
antibacterial agent
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4008-48-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Nitroxoline has been clinically used since 1962 for the treatment of urinary tract infections, especially those caused by gram negative bacilli. The current renewal of nitroxoline is due to its recently found activity against fungi, U. urealyticum, Mycoplasma, and Trichomonas.
In vitro: The machnistic study showed that nitroxoline, in the treatment of acute or recurrent urinary tract infections caused by Escherichia coli, could be decreased in the presence of Mg2+ and Mn2+ but not Ca2+. Moreover, with the divalent metal ions, a shift in the nitroxoline A448 indicated the formation of drug-ion complexes and a clear correlation was observed between the chelating property and antibacterial activity of nitroxolinet. In addition, it was found that the uptake was energy-independent and with biphasic kinetics: a rapid cell association phase and then a slower increase of cell- nitroxoline association [1].
In vivo: Previous animal study showed that nitroxoline suspension with Tween-80 in a could decrease the tone of the rat and guinea-pig ileum and diminish their peristalsis. Moreover, when administered orally in a dose 50 mg/kg to rats, nitroxoline was able to inhibit the agar-, serotonin-, as well as carrageenin-induced edemas of the rat paws without affecting the response to subplantar histamine injection [2].
Clinical trial: Twelve children were treated with nitroxoline (200 mg/kg/d) during 10 days for urinary tract infection. The results showed eight clinical and bacteriological success, one true failure, and three failure because of a non-compliance to the nitroxoline treatment. In addition, there was no qualitative and quantitative modification of the fecal flora observed after nitroxoline treatment [3].
References:
[1] Pelletier C,Prognon P,Bourlioux P. Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains. Antimicrob Agents Chemother.1995 Mar;39(3):707-13.
[2] Zaks AS,Zil'ber AL,Kapitonenko TA. Spasmolytic and anti-inflammatory activity of 8-hydroxyquinolines. Farmakol Toksikol.1984 Sep-Oct;47(5):44-7.
[3] Lambert-Zechovsky N,Lévêque B,Bingen E,Pillion G,Chapelle J,Mathieu H. Clinical study and effect of nitroxoline on fecal flora in childrenPathol Biol (Paris).1987 May;35(5):669-72.
| Cas No. | 4008-48-4 | SDF | |
| Synonyms | 8-Hydroxy-5-nitroquinoline, 5-Nitro-8-hydroxyquinoline | ||
| Chemical Name | 5-nitroquinolin-8-ol | ||
| Canonical SMILES | OC1=C2C(C=CC=N2)=C(N(=O)=O)C=C1 | ||
| Formula | C9H6N2O3 | M.Wt | 190.16 |
| Solubility | DMF: 25 mg/ml,DMSO: 30 mg/ml,Ethanol: 1 mg/ml,PBS (pH 7.2): 0.5 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 5.2587 mL | 26.2936 mL | 52.5873 mL |
| 5 mM | 1.0517 mL | 5.2587 mL | 10.5175 mL |
| 10 mM | 525.9 μL | 2.6294 mL | 5.2587 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)